皮下免疫グロブリン（SCIG）の世界市場レポート 2025年

皮下免疫グロブリン（SCIG）の市場規模は今後数年で急成長が見込まれます。2029年にはCAGR13.7％で242億9,000万米ドルに成長します。予測期間の成長は、神経疾患の有病率の増加、自己免疫疾患の有病率の増加、免疫グロブリン療法に対する認識と受容の高まり、神経学と皮膚科学におけるアプリケーションの拡大、ヘルスケア施設の拡大などに起因すると考えられます。予測期間における主な動向としては、ドラッグデリバリーシステムの進歩、在宅輸液療法の需要増加、抗体療法の開発、製剤の革新、SCIGの革新などが挙げられます。

二次性免疫不全症の有病率の上昇が、今後の皮下免疫グロブリン市場の成長を牽引すると予想されます。二次性免疫不全症は、先天的な免疫不全以外の要因による免疫系の機能低下を特徴とします。この流行は、人口の高齢化、免疫抑制療法の使用、環境毒素への暴露などの要因によって促進されています。皮下免疫グロブリン療法は、特にHIVや自己免疫疾患などの慢性疾患において、弱った免疫系を強化する抗体を投与することにより、感染症を予防し、治療中の免疫機能をサポートします。例えば、2023年10月、英国健康安全保障局は、2022年にイングランドで新たにHIVと診断されたのは3,805人で、前年から22％増加したと報告しています。したがって、二次性免疫不全疾患の有病率の上昇が皮下免疫グロブリン市場の成長を促進しています。

神経疾患の罹患率の増加も、皮下免疫グロブリン市場の拡大に寄与すると予想されています。神経疾患は、脳、脊髄、末梢神経における解剖学的、生化学的、電気的異常を特徴とする、神経系に影響を及ぼすさまざまな状態を包含します。人口の高齢化、環境汚染物質、遺伝的素因、ライフスタイルの変化などの要因が、神経疾患の有病率の増加に寄与しています。皮下免疫グロブリン療法は、免疫反応を調節し、炎症を抑え、神経筋接合部を安定化させる抗体を提供することにより、これらの疾患において有益であり、疾患の進行を遅らせ、症状を改善する可能性があります。例えば、アルツハイマー病協会によれば、65歳以上のアメリカ人のうち650万人がアルツハイマー型認知症を患っており、2060年までにこの数は2倍の1,380万人になると予測されています。したがって、神経疾患の増加が皮下免疫グロブリン市場の成長を牽引しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、新型コロナウイルス感染症、そして景気回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界皮下免疫グロブリン（SCIG） PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の皮下免疫グロブリン（SCIG）市場：成長率分析
• 世界の皮下免疫グロブリン（SCIG）市場の実績：規模と成長, 2019-2024
• 世界の皮下免疫グロブリン（SCIG）市場の予測：規模と成長, 2024-2029, 2034F
• 世界皮下免疫グロブリン（SCIG）総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の皮下免疫グロブリン（SCIG）市場：製品タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 免疫グロブリンA（IgA）
• 免疫グロブリンG（IgG）
• 免疫グロブリンM（IgM）
• 世界の皮下免疫グロブリン（SCIG）市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 原発性免疫不全症
• 自己免疫疾患
• 神経疾患
• その他の用途
• 世界の皮下免疫グロブリン（SCIG）市場：最終用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• クリニック
• 病院
• ホームケア
• その他の用途
• 世界の皮下免疫グロブリン（SCIG）市場免疫グロブリンA（IgA）のサブセグメンテーション（タイプ別）、実績と予測, 2019-2024, 2024-2029F, 2034F
• IgA1
• IgA2
• 世界の皮下免疫グロブリン（SCIG）市場免疫グロブリンG（IgG）のサブセグメンテーション（タイプ別）、実績と予測, 2019-2024, 2024-2029F, 2034F
• IgG1
• IgG2
• IgG3
• IgG4
• 世界の皮下免疫グロブリン（SCIG）市場免疫グロブリンM（IgM）のサブセグメンテーション（タイプ別）、実績と予測, 2019-2024, 2024-2029F, 2034F
• 五量体IgM
• 六量体IgM

第7章 地域別・国別分析

• 世界の皮下免疫グロブリン（SCIG）市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の皮下免疫グロブリン（SCIG）市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 皮下免疫グロブリン（SCIG）市場：競合情勢
• 皮下免疫グロブリン（SCIG）市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • Prothena Corporation plc Overview, Products and Services, Strategy and Financial Analysis
  • GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
  • Takeda Pharmaceutical Company Limited Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Amgen Inc.
• Baxter International Inc.
• CSL Behring
• Lonza Group
• Grifols S.A.
• Octapharma AG
• Dr. Reddy's Laboratories
• Intas Pharmaceutical Ltd.
• Emergent BioSolutions Inc.
• Kedrion Biopharma
• LFB Group
• Biotest AG
• Argenx SE
• Bio Products Laboratory Ltd.
• ADMA Biologics Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 皮下免疫グロブリン（SCIG）市場2029：新たな機会を提供する国
• 皮下免疫グロブリン（SCIG）市場2029：新たな機会を提供するセグメント
• 皮下免疫グロブリン（SCIG）市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Subcutaneous immunoglobulin (SCIG) refers to a method of administering immunoglobulin therapy where the medication is injected under the skin, rather than into a vein. This approach allows for slower absorption of the medication, which can reduce the risk of side effects compared to intravenous administration. SCIG is commonly used to treat various immune deficiencies, providing a convenient and effective way to boost the immune system.

The main types of SCIG products include immunoglobulin A (IgA), immunoglobulin G (IgG), and immunoglobulin M (IgM). IgA is an antibody type crucial for immune defense at mucosal surfaces, helping prevent pathogens from entering the body through mucosal membranes. These products find applications in primary immunodeficiency disorders, autoimmune diseases, neurological disorders, and other conditions, and they are used by various end-users such as clinics, hospitals, homecare settings, and others.

The subcutaneous immunoglobulin (SCIG) market research report is one of a series of new reports from The Business Research Company that provides subcutaneous immunoglobulin (SCIG) market statistics, including the subcutaneous immunoglobulin (SCIG) industry global market size, regional shares, competitors with subcutaneous immunoglobulin (SCIG) market share, detailed subcutaneous immunoglobulin (SCIG) market segments, market trends, and opportunities, and any further data you may need to thrive in the subcutaneous immunoglobulin (SCIG) industry. These subcutaneous immunoglobulin (SCIG) market research reports deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The subcutaneous immunoglobulin (SCIG) market size has grown rapidly in recent years. It will grow from $12.72 billion in 2024 to $14.52 billion in 2025 at a compound annual growth rate (CAGR) of 14.1%. The growth in the historic period can be attributed to the increased prevalence of immunodeficiency disorders, rise in the patient preference for home-based care, enhanced therapeutic efficacy, growth in the awareness and diagnosis rates, growth in the favorable reimbursement policies.

The subcutaneous immunoglobulin (SCIG) market size is expected to see rapid growth in the next few years. It will grow to $24.29 billion in 2029 at a compound annual growth rate (CAGR) of 13.7%. The growth in the forecast period can be attributed to the growing prevalence of neurological disorders, increasing prevalence of autoimmune diseases, rising awareness and acceptance of immunoglobulin therapy, expanding applications in neurology and dermatology, expansion of healthcare facilities. Major trends in the forecast period include advancements in drug delivery systems, increasing demand for home infusion therapies, developments in antibody therapy, Innovations in formulations, and Innovations in SCIG.

The rising prevalence of secondary immunodeficiency diseases is expected to drive the growth of the subcutaneous immunoglobulin market in the future. Secondary immunodeficiency diseases are characterized by a compromised immune system due to factors other than inherent immune system deficiencies. This prevalence is fueled by factors such as aging populations, the use of immunosuppressive therapies, and exposure to environmental toxins. Subcutaneous immunoglobulin therapy delivers antibodies to bolster the weakened immune system, particularly in chronic conditions such as HIV or autoimmune disorders, thereby preventing infections and supporting immune function during treatment. For example, in October 2023, the UK Health Security Agency reported 3,805 new HIV diagnoses in England in 2022, marking a 22% increase from the previous year. Hence, the rising prevalence of secondary immunodeficiency diseases is propelling the growth of the subcutaneous immunoglobulin market.

The growing incidence of neurological disorders is also expected to contribute to the expansion of the subcutaneous immunoglobulin market. Neurological disorders encompass a range of conditions affecting the nervous system, characterized by anatomical, biochemical, or electrical abnormalities in the brain, spinal cord, or peripheral nerves. Factors such as aging populations, environmental pollutants, genetic predispositions, and lifestyle changes contribute to the increasing prevalence of neurological disorders. Subcutaneous immunoglobulin therapy can be beneficial in these disorders by providing antibodies that modulate immune responses, reduce inflammation, and stabilize neuromuscular junctions, potentially slowing disease progression and improving symptoms. For instance, according to the Alzheimer's Association, 6.5 million Americans aged 65 and older are living with Alzheimer's dementia, with projections suggesting this number could double to 13.8 million by 2060. Hence, the rising number of neurological disorders is driving the growth of the subcutaneous immunoglobulin market.

Leading companies in the subcutaneous immunoglobulin market are developing subcutaneous human immunoglobulin (SCIG) formulations to enhance their product portfolios and offer more treatment options for patients with primary immunodeficiency diseases. SCIG refers to human immunoglobulin formulations for subcutaneous administration, designed specifically for treating primary immunodeficiency diseases. For example, in March 2022, Grifols S.A. introduced XEMBIFY 20% SCIG, a ready-to-use formulation for treating primary immunodeficiency, addressing a significant medical need for individuals with weakened immune systems. XEMBIFY offers simplified treatment procedures and increased patient convenience, as it remains stable at room temperature for up to 24 months, eliminating the need for refrigeration during storage and transport, which is advantageous in various healthcare settings.

Major companies operating in the subcutaneous immunoglobulin (SCIG) market are Pfizer Inc., Johnson & Johnson, Prothena Corporation plc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Amgen Inc., Baxter International Inc., CSL Behring, Lonza Group, Grifols S.A., Octapharma AG, Dr. Reddy's Laboratories, Intas pharmaceutical Ltd., Emergent BioSolutions Inc., Kedrion Biopharma, LFB group, Biotest AG, Argenx SE, Bio Products Laboratory Ltd., ADMA Biologics Inc., Sino Biological Inc., Bharat Serums and Vaccines Limited (BSV), Kamada Pharmaceuticals, CinnaGen Co., Shire plc

North America was the largest region in the subcutaneous immunoglobulin market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the subcutaneous immunoglobulin (SCIG) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the subcutaneous immunoglobulin (SCIG) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The subcutaneous immunoglobulin (SCIG) market consists of revenues earned by entities by providing services such as immune system support, home-based therapy, infection prevention, personalized dosing, patient training, and support. The market value includes the value of related goods sold by the service provider or included within the service offering. The subcutaneous immunoglobulin market also includes sales of infusion pumps, needles and catheters, syringes, and sharps disposal containers. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Subcutaneous Immunoglobulin (SCIG) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on subcutaneous immunoglobulin (scig) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for subcutaneous immunoglobulin (scig) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The subcutaneous immunoglobulin (scig) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Product Type: Immunoglobulin A (IgA); Immunoglobulin G (IgG); Immunoglobulin M (IgM)
• 2) By Application: Primary Immunodeficiency Disorders; Autoimmune Diseases; Neurological Disorders; Other Applications
• 3) By End-Use: Clinics; Hospitals; Homecare; Other End-Uses
• Subsegments:
• 1) By Immunoglobulin A (IgA): IgA1; IgA2
• 2) By Immunoglobulin G (IgG): IgG1; IgG2; IgG3; IgG4
• 3) By Immunoglobulin M (IgM): Pentameric IgM; Hexameric IgM
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson; Prothena Corporation plc; GlaxoSmithKline plc; Takeda Pharmaceutical Company Limited
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Subcutaneous Immunoglobulin (SCIG) Market Characteristics

3. Subcutaneous Immunoglobulin (SCIG) Market Trends And Strategies

4. Subcutaneous Immunoglobulin (SCIG) Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Subcutaneous Immunoglobulin (SCIG) Growth Analysis And Strategic Analysis Framework

• 5.1. Global Subcutaneous Immunoglobulin (SCIG) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Subcutaneous Immunoglobulin (SCIG) Market Growth Rate Analysis
• 5.4. Global Subcutaneous Immunoglobulin (SCIG) Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Subcutaneous Immunoglobulin (SCIG) Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Subcutaneous Immunoglobulin (SCIG) Total Addressable Market (TAM)

6. Subcutaneous Immunoglobulin (SCIG) Market Segmentation

• 6.1. Global Subcutaneous Immunoglobulin (SCIG) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Immunoglobulin A (IgA)
• Immunoglobulin G (IgG)
• Immunoglobulin M (IgM)
• 6.2. Global Subcutaneous Immunoglobulin (SCIG) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Primary Immunodeficiency Disorders
• Autoimmune Diseases
• Neurological Disorders
• Other Applications
• 6.3. Global Subcutaneous Immunoglobulin (SCIG) Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Clinics
• Hospitals
• Homecare
• Other End-Uses
• 6.4. Global Subcutaneous Immunoglobulin (SCIG) Market, Sub-Segmentation Of Immunoglobulin A (IgA), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• IgA1
• IgA2
• 6.5. Global Subcutaneous Immunoglobulin (SCIG) Market, Sub-Segmentation Of Immunoglobulin G (IgG), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• IgG1
• IgG2
• IgG3
• IgG4
• 6.6. Global Subcutaneous Immunoglobulin (SCIG) Market, Sub-Segmentation Of Immunoglobulin M (IgM), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pentameric IgM
• Hexameric IgM

7. Subcutaneous Immunoglobulin (SCIG) Market Regional And Country Analysis

• 7.1. Global Subcutaneous Immunoglobulin (SCIG) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Subcutaneous Immunoglobulin (SCIG) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Subcutaneous Immunoglobulin (SCIG) Market

• 8.1. Asia-Pacific Subcutaneous Immunoglobulin (SCIG) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Subcutaneous Immunoglobulin (SCIG) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Subcutaneous Immunoglobulin (SCIG) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Subcutaneous Immunoglobulin (SCIG) Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Subcutaneous Immunoglobulin (SCIG) Market

• 9.1. China Subcutaneous Immunoglobulin (SCIG) Market Overview
• 9.2. China Subcutaneous Immunoglobulin (SCIG) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Subcutaneous Immunoglobulin (SCIG) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Subcutaneous Immunoglobulin (SCIG) Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Subcutaneous Immunoglobulin (SCIG) Market

• 10.1. India Subcutaneous Immunoglobulin (SCIG) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Subcutaneous Immunoglobulin (SCIG) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Subcutaneous Immunoglobulin (SCIG) Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Subcutaneous Immunoglobulin (SCIG) Market

• 11.1. Japan Subcutaneous Immunoglobulin (SCIG) Market Overview
• 11.2. Japan Subcutaneous Immunoglobulin (SCIG) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Subcutaneous Immunoglobulin (SCIG) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Subcutaneous Immunoglobulin (SCIG) Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Subcutaneous Immunoglobulin (SCIG) Market

• 12.1. Australia Subcutaneous Immunoglobulin (SCIG) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Subcutaneous Immunoglobulin (SCIG) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Subcutaneous Immunoglobulin (SCIG) Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Subcutaneous Immunoglobulin (SCIG) Market

• 13.1. Indonesia Subcutaneous Immunoglobulin (SCIG) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Subcutaneous Immunoglobulin (SCIG) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Subcutaneous Immunoglobulin (SCIG) Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Subcutaneous Immunoglobulin (SCIG) Market

• 14.1. South Korea Subcutaneous Immunoglobulin (SCIG) Market Overview
• 14.2. South Korea Subcutaneous Immunoglobulin (SCIG) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Subcutaneous Immunoglobulin (SCIG) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Subcutaneous Immunoglobulin (SCIG) Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Subcutaneous Immunoglobulin (SCIG) Market

• 15.1. Western Europe Subcutaneous Immunoglobulin (SCIG) Market Overview
• 15.2. Western Europe Subcutaneous Immunoglobulin (SCIG) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Subcutaneous Immunoglobulin (SCIG) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Subcutaneous Immunoglobulin (SCIG) Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Subcutaneous Immunoglobulin (SCIG) Market

• 16.1. UK Subcutaneous Immunoglobulin (SCIG) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Subcutaneous Immunoglobulin (SCIG) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Subcutaneous Immunoglobulin (SCIG) Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Subcutaneous Immunoglobulin (SCIG) Market

• 17.1. Germany Subcutaneous Immunoglobulin (SCIG) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Subcutaneous Immunoglobulin (SCIG) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Subcutaneous Immunoglobulin (SCIG) Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Subcutaneous Immunoglobulin (SCIG) Market

• 18.1. France Subcutaneous Immunoglobulin (SCIG) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Subcutaneous Immunoglobulin (SCIG) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Subcutaneous Immunoglobulin (SCIG) Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Subcutaneous Immunoglobulin (SCIG) Market

• 19.1. Italy Subcutaneous Immunoglobulin (SCIG) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Subcutaneous Immunoglobulin (SCIG) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Subcutaneous Immunoglobulin (SCIG) Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Subcutaneous Immunoglobulin (SCIG) Market

• 20.1. Spain Subcutaneous Immunoglobulin (SCIG) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Subcutaneous Immunoglobulin (SCIG) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Subcutaneous Immunoglobulin (SCIG) Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Subcutaneous Immunoglobulin (SCIG) Market

• 21.1. Eastern Europe Subcutaneous Immunoglobulin (SCIG) Market Overview
• 21.2. Eastern Europe Subcutaneous Immunoglobulin (SCIG) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Subcutaneous Immunoglobulin (SCIG) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Subcutaneous Immunoglobulin (SCIG) Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Subcutaneous Immunoglobulin (SCIG) Market

• 22.1. Russia Subcutaneous Immunoglobulin (SCIG) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Subcutaneous Immunoglobulin (SCIG) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Subcutaneous Immunoglobulin (SCIG) Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Subcutaneous Immunoglobulin (SCIG) Market

• 23.1. North America Subcutaneous Immunoglobulin (SCIG) Market Overview
• 23.2. North America Subcutaneous Immunoglobulin (SCIG) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Subcutaneous Immunoglobulin (SCIG) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Subcutaneous Immunoglobulin (SCIG) Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Subcutaneous Immunoglobulin (SCIG) Market

• 24.1. USA Subcutaneous Immunoglobulin (SCIG) Market Overview
• 24.2. USA Subcutaneous Immunoglobulin (SCIG) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Subcutaneous Immunoglobulin (SCIG) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Subcutaneous Immunoglobulin (SCIG) Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Subcutaneous Immunoglobulin (SCIG) Market

• 25.1. Canada Subcutaneous Immunoglobulin (SCIG) Market Overview
• 25.2. Canada Subcutaneous Immunoglobulin (SCIG) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Subcutaneous Immunoglobulin (SCIG) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Subcutaneous Immunoglobulin (SCIG) Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Subcutaneous Immunoglobulin (SCIG) Market

• 26.1. South America Subcutaneous Immunoglobulin (SCIG) Market Overview
• 26.2. South America Subcutaneous Immunoglobulin (SCIG) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Subcutaneous Immunoglobulin (SCIG) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Subcutaneous Immunoglobulin (SCIG) Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Subcutaneous Immunoglobulin (SCIG) Market

• 27.1. Brazil Subcutaneous Immunoglobulin (SCIG) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Subcutaneous Immunoglobulin (SCIG) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Subcutaneous Immunoglobulin (SCIG) Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Subcutaneous Immunoglobulin (SCIG) Market

• 28.1. Middle East Subcutaneous Immunoglobulin (SCIG) Market Overview
• 28.2. Middle East Subcutaneous Immunoglobulin (SCIG) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Subcutaneous Immunoglobulin (SCIG) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Subcutaneous Immunoglobulin (SCIG) Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Subcutaneous Immunoglobulin (SCIG) Market

• 29.1. Africa Subcutaneous Immunoglobulin (SCIG) Market Overview
• 29.2. Africa Subcutaneous Immunoglobulin (SCIG) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Subcutaneous Immunoglobulin (SCIG) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Subcutaneous Immunoglobulin (SCIG) Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Subcutaneous Immunoglobulin (SCIG) Market Competitive Landscape And Company Profiles

• 30.1. Subcutaneous Immunoglobulin (SCIG) Market Competitive Landscape
• 30.2. Subcutaneous Immunoglobulin (SCIG) Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Prothena Corporation plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Takeda Pharmaceutical Company Limited Overview, Products and Services, Strategy and Financial Analysis

31. Subcutaneous Immunoglobulin (SCIG) Market Other Major And Innovative Companies

• 31.1. Amgen Inc.
• 31.2. Baxter International Inc.
• 31.3. CSL Behring
• 31.4. Lonza Group
• 31.5. Grifols S.A.
• 31.6. Octapharma AG
• 31.7. Dr. Reddy's Laboratories
• 31.8. Intas Pharmaceutical Ltd.
• 31.9. Emergent BioSolutions Inc.
• 31.10. Kedrion Biopharma
• 31.11. LFB Group
• 31.12. Biotest AG
• 31.13. Argenx SE
• 31.14. Bio Products Laboratory Ltd.
• 31.15. ADMA Biologics Inc.

32. Global Subcutaneous Immunoglobulin (SCIG) Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Subcutaneous Immunoglobulin (SCIG) Market

34. Recent Developments In The Subcutaneous Immunoglobulin (SCIG) Market

35. Subcutaneous Immunoglobulin (SCIG) Market High Potential Countries, Segments and Strategies

• 35.1 Subcutaneous Immunoglobulin (SCIG) Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Subcutaneous Immunoglobulin (SCIG) Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Subcutaneous Immunoglobulin (SCIG) Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer